T. Valdez

572 total citations · 1 hit paper
17 papers, 326 citations indexed

About

T. Valdez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, T. Valdez has authored 17 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in T. Valdez's work include Advanced Breast Cancer Therapies (10 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (7 papers). T. Valdez is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), HER2/EGFR in Cancer Research (10 papers) and Cancer Treatment and Pharmacology (7 papers). T. Valdez collaborates with scholars based in United States, Spain and Germany. T. Valdez's co-authors include Hope S. Rugo, Olivier Trédan, Wendy Verret, Sara M. Tolaney, Aditya Bardia, Frederik Marmé, Javier Cortés, Hao Wang, Florence Dalenc and Komal Jhaveri and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

T. Valdez

15 papers receiving 323 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

2023 210 citations Hope S. Rugo, Aditya Bardia et al. The Lancet profile →

Peers

Countries citing papers authored by T. Valdez

Since Specialization

Citations

This map shows the geographic impact of T. Valdez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Valdez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Valdez more than expected).

Fields of papers citing papers by T. Valdez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Valdez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Valdez. The network helps show where T. Valdez may publish in the future.

Co-authorship network of co-authors of T. Valdez

This figure shows the co-authorship network connecting the top 25 collaborators of T. Valdez. A scholar is included among the top collaborators of T. Valdez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Valdez. T. Valdez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	LBA20 Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i) 2025 ·Annals of Oncology ·J.‐C. Cortés, (unknown), (unknown), Carlos H. Barrios, (unknown), (unknown), (unknown), (unknown), Adam Brufsky, (unknown), (unknown), (unknown), (unknown), Alessandra Fabi, (unknown), T. Valdez, Xuchen Zhang, Catherine Lai, (unknown)	0
2	Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States 2025 ·ESMO Open ·Rita Nanda, Clinton Yam, Laura M. Spring, (unknown), (unknown), T. Valdez, (unknown), Chang Yin Liang, Wenhui Wu, (unknown), Natalia Sadetsky, Catherine Lai, (unknown)	0
3	The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study 2025 ·ESMO Open ·Laura García‐Estévez, Aditya Bardia, Hope S. Rugo, Lisa A. Carey, Véronique Dièras, Sibylle Loibl, Martine Piccart, Luca Gianni, Kevin Kalinsky, Joyce O’Shaughnessy, Sara A. Hurvitz, Eliza Harting, T. Valdez, S. Phan, (unknown), Javier Cortés	1
4	Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 2025 ·New England Journal of Medicine ·Javier Cortés, Kevin Punie, Carlos H. Barrios, Sara A. Hurvitz, Andreas Schneeweiß, Joohyuk Sohn, Eriko Tokunaga, Adam Brufsky, Yeon Hee Park, (unknown), Roberto Hegg, Mafalda Oliveira, Alessandra Fabi, Natalya Vaksman, T. Valdez, (unknown), Catherine Lai, Sara M. Tolaney	4
5	Abstract PO5-21-09: Clinical outcomes by age subgroups in the phase 3 TROPiCS-02 study of sacituzumab govitecan vs treatment of physician’s choice in HR+/HER2‒ metastatic breast cancer 2024 ·Cancer Research ·Aditya Bardia, Peter Schmid, Sara M. Tolaney, Frederik Marmé, Javier Cortés, T. Valdez, Hao Wang, Wendy Verret, Hope Rugo	3
6	Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial 2024 ·Nature Medicine ·Binghe Xu, Shusen Wang, Min Yan, Joohyuk Sohn, Wei Li, (unknown), Xiaojia Wang, Ying Wang, Seock‐Ah Im, Dongdong Jiang, T. Valdez, (unknown), Yiran Zhang, Yi‐Lin Yan, Kimberly M. Komatsubara, Wei‐Pang Chung, Fei Ma, Ming‐Shen Dai	14
7	PS3-2 Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2− metastatic breast cancer 2024 ·Annals of Oncology ·(unknown), (unknown), F. Marmé, Javier Cortés, Patrick Schmid, (unknown), (unknown), (unknown), (unknown), (unknown), Komal Jhaveri, (unknown), T. Valdez, Oh Kyu Yoon, (unknown), (unknown), (unknown)	1
8	Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types. 2024 ·Journal of Clinical Oncology ·Hope S. Rugo, Sara M. Tolaney, Aditya Bardia, Javier Cortes, Frederik Marmé, Peter Schmid, Lisa A. Carey, Sibylle Loibl, Kevin Kalinsky, Joyce O’Shaughnessy, Sara A. Hurvitz, T. Valdez, Ya Meng, Wendy Verret, Scott T. Tagawa	4
9	189P The impact of high body mass index (BMI) on the safety and efficacy of sacituzumab govitecan (SG) in patients (pts) with metastatic triple-negative breast cancer (mTNBC) from ASCENT 2024 ·ESMO Open ·(unknown), (unknown), (unknown), Lisa A. Carey, Véronique Dièras, (unknown), Martine Piccart, (unknown), (unknown), Joyce O’Shaughnessy, Sara A. Hurvitz, Eliza Harting, T. Valdez, (unknown), Chyong‐Huey Lai, Javier Cortés	3
10	194P Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC) 2023 ·ESMO Open ·Frederik Marmé, Hope S. Rugo, Sara M. Tolaney, Aditya Bardia, Peter Schmid, Wendy Verret, T. Valdez, (unknown), Javier Cortés	9
11	389P Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) 2023 ·Annals of Oncology ·Javier Cortés, Frederik Marmé, Peter Schmid, (unknown), (unknown), Wendy Verret, T. Valdez, Yuankai Huo, Aditya Bardia	2
12	LBA4 Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC): Results from the phase III EVER-002 study 2023 ·Annals of Oncology ·(unknown), Fei Ma, Shiyan Wang, Ming Yan, Wei Li, Jong‐Woo Sohn, Jie Tang, Xiao Hua Wang, Yang Wang, S-A. Im, Dongneng Jiang, T. Valdez, Yong Zhang, (unknown), (unknown)	5
13	54O Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2– metastatic breast cancer (mBC) 2023 ·Annals of Oncology ·(unknown), Frederik Marmé, Hope S. Rugo, Sara M. Tolaney, Aditya Bardia, Patrick Schmid, Wendy Verret, T. Valdez, (unknown), Javier Cortés	1
14	Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial breakdown → 2023 ·The Lancet ·Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, P. Gómez Pardo, Komal Jhaveri, Rosemary Delaney, T. Valdez, Hao Wang, Monica Motwani, Oh Kyu Yoon, Wendy Verret, Sara M. Tolaney	210
15	198P Relationship of diarrhea and neutropenia events with outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG): Post hoc analysis from the phase III ASCENT study 2023 ·ESMO Open ·Evandro de Azambuja, (unknown), Matteo Lambertini, Hope S. Rugo, Aditya Bardia, Sara M. Tolaney, Joyce O’Shaughnessy, Rosemary Delaney, Shan Zha, (unknown), T. Valdez, (unknown), Elisa Agostinetto	1
16	Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). 2023 ·Journal of Clinical Oncology ·Sara M. Tolaney, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, P. Gómez Pardo, Komal Jhaveri, Rosemary Delaney, T. Valdez, Oh Kyu Yoon, Hao Wang, Wendy Verret, Hope S. Rugo	26
17	LBA76 Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) 2022 ·Annals of Oncology ·Hope S. Rugo, (unknown), (unknown), (unknown), P. Schmid, (unknown), Olivier Trédan, (unknown), (unknown), (unknown), (unknown), (unknown), T. Valdez, (unknown), (unknown), (unknown)	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact